Notch Signaling Pathway in Adenoid Cystic Carcinoma: A Review

doi:10.13701/j.cnki.kqyxyj.2023.12.003

Abstract

Abstract: Adenoid cystic carcinoma is a rare kind of malignancy in secretory glands, usually occurs in salivary glands. It is characterized by perineural invasion and early hematogenous metastasis, presenting difficulties to its clinical treatment. Recent studies have found that Notch signaling pathway plays an important role in the development and metastasis of adenoid cystic carcinoma, and presents attractive prognostic indicators and drug targets. This article reviews the research progress of regulatory mechanisms and drug targets in adenoid cystic carcinoma based on Notch signaling pathway.

Key words: adenoid cystic carcinoma, Notch signaling pathway, prognostic biomarker, targeted therapy

LI Zhi, CHEN Wei. Notch Signaling Pathway in Adenoid Cystic Carcinoma: A Review[J]. Journal of Oral Science Research, 2023, 39(12): 1042-1045.

References

[1] Dewenter I, Otto S, Kakoschke TK, et al. Recent advances, systemic therapy, and molecular targets in adenoid cystic carcinoma of the head and neck [J]. J Clin Med, 2023, 12(4): 1463.
[2] Ferreira A, Aster JC. Notch signaling in cancer: Complexity and challenges on the path to clinical translation [J]. Semin Cancer Biol, 2022, 85: 95-106.
[3] Xia R, Xu M, Yang J, et al. The role of Hedgehog and Notch signaling pathway in cancer [J]. Mol Biomed, 2022, 3(1): 44.
[4] Parikh AS, Wizel A, Davis D, et al. Single-cell RNA sequencing identifies a paracrine interaction that may drive oncogenic notch signaling in human adenoid cystic carcinoma [J]. Cell Rep, 2022, 41(9): 111743.
[5] Wang Y, Sun B, Zhang C, et al. Genetic heterogeneity and therapeutic target detection through microdissection in solid-type adenoid cystic carcinoma [J]. Pathology, 2022, 54(5): 580-590.
[6] Xie M, Wei S, Wu X, et al. Alterations of Notch pathway in patients with adenoid cystic carcinoma of the trachea and its impact on survival [J]. Lung Cancer, 2018, 121: 41-47.
[7] Xie J, Lin LS, Huang XY, et al. The NOTCH1-HEY1 pathway regulates self-renewal and epithelial-mesenchymal transition of salivary adenoid cystic carcinoma cells [J]. Int J Biol Sci, 2020, 16(4): 598-610.
[8] Huang XY, Gan RH, Xie J, et al. The oncogenic effects of HES1 on salivary adenoid cystic carcinoma cell growth and metastasis [J]. BMC Cancer, 2018, 18(1): 436.
[9] Anjum S, Sen S, Pushker N, et al. Prognostic impact of Notch1 receptor and clinicopathological High-Risk Predictors in lacrimal gland adenoid cystic carcinoma [J]. Acta Ophthalmol, 2021, 99(8): e1467-e1473.
[10] Li Z, Zhang Q, Su H, et al. miR-5191 acts as a tumor suppressor in salivary adenoid cystic carcinoma by targeting Notch-2 [J]. Oral Dis, 2022, 28(7): 1871-1881.
[11] Wang K, Fan HY, Pang X, et al. Dll4/Notch1 signalling pathway is required in collective invasion of salivary adenoid cystic carcinoma [J]. Oncol Rep, 2021, 45(3): 1011-1022.
[12] Masse J, Truntzer C, Boidot R, et al. Solid-type adenoid cystic carcinoma of the breast, a distinct molecular entity enriched in NOTCH and CREBBP mutations [J]. Mod Pathol, 2020, 33(6): 1041-1055.
[13] Wang Y, Han Y, Xu SM, et al. Targeting EGFR enriches stem cell-like properties in salivary adenoid cystic carcinoma by activating the Notch1 pathway [J]. Cancer Manag Res, 2020, 12: 6655-6663.
[14] Feeney L, Hapuarachi B, Adderley H, et al. Clinical disease course and survival outcomes following disease recurrence in adenoid cystic carcinoma with and without NOTCH signaling pathway activation [J]. Oral Oncol, 2022, 133: 106028.
[15] You WK, Schuetz TJ, Lee SH. Targeting the DLL/Notch signaling pathway in cancer: Challenges and advances in clinical development [J]. Mol Cancer Ther, 2023, 22(1): 3-11.
[16] Mccaw TR, Inga E, Chen H, et al. Gamma secretase inhibitors in cancer: A current perspective on clinical performance [J]. Oncologist, 2021, 26(4): e608-e621.
[17] Lee RH, Wai KC, Chan JW, et al. Approaches to the management of metastatic adenoid cystic carcinoma [J]. Cancers (Basel), 2022, 14(22): 5698.
[18] Ferrarotto R, Mishra V, Herz E, et al. AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling [J]. Cell Death Dis, 2022, 13(8): 678.
[19] Kieran R, De Paula BHR, Hubank M, et al. Response of NOTCH1-activated tracheal adenoid cystic carcinoma to the gamma secretase inhibitor nirogacestat [J]. JCO Precis Oncol, 2021, 5: 1579-1583.
[20] Miller LE, Au V, Mokhtari TE, et al. A contemporary review of molecular therapeutic targets for adenoid cystic carcinoma [J]. Cancers (Basel), 2022, 14(4): 992.
[21] Smith DC, Chugh R, Patnaik A, et al. A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors [J]. Invest New Drugs, 2019, 37(4): 722-730.
[22] Spriano F, Tarantelli C, Arribas AJ, et al. In vitro anti-lymphoma activity of the first-in-class pan-NOTCH transcription inhibitor CB-103 [J]. Br J Haematol, 2023, 200(5): 669-672.
[23] Lehal R, Zaric J, Vigolo M, et al. Pharmacological disruption of the Notch transcription factor complex [J]. Proc Natl Acad Sci U S A, 2020, 117(28): 16292-16301.
[24] Arai MA, Akamine R, Tsuchiya A, et al. The Notch inhibitor cowanin accelerates nicastrin degradation [J]. Sci Rep, 2018, 8(1): 5376.
[25] Hashemi M, Hasani S, Hajimazdarany S, et al. Non-coding RNAs targeting notch signaling pathway in cancer: From proliferation to cancer therapy resistance [J]. Int J Biol Macromol, 2022, 222(Pt A): 1151-1167.
[26] 谢茜,赵云,刘蓉,等.超声微泡介导的miRNA递送在恶性肿瘤治疗中的应用[J].生命的化学, 2020, 40(12): 2193-2199.
[27] 井汇源,曹素芳,刘影,等.基于RNA病毒的microRNA递送载体研究进展[J].生命的化学, 2021, 41(3): 519-525.
[28] Valcourt DM, Dang MN, Wang J, et al. Nanoparticles for manipulation of the developmental Wnt, Hedgehog, and Notch signaling pathways in cancer [J]. Ann Biomed Eng, 2020, 48(7): 1864-1884.